OraSure Technologies, Inc. (NASDAQ:OSUR) Short Interest Update – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
OraSure Technologies, Inc. (NASDAQ:OSUR – Get Rating) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 3,540,000 shares, an increase of 19.2% from the July 15th total of 2,970,000 shares. Based on an average daily trading volume, of 1,420,000 shares, the days-to-cover ratio is currently 2.5 days. Currently, 5.1% of the company’s stock are sold short.
Institutional Trading of OraSure Technologies
A number of hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC boosted its stake in OraSure Technologies by 249.6% during the second quarter. FMR LLC now owns 10,687 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 7,630 shares in the last quarter. 1832 Asset Management L.P. purchased a new position in OraSure Technologies in the 1st quarter worth about $40,000. Legacy Advisors LLC raised its holdings in OraSure Technologies by 68.6% during the 2nd quarter. Legacy Advisors LLC now owns 20,650 shares of the medical instruments supplier’s stock worth $56,000 after buying an additional 8,403 shares during the period. Russell Investments Group Ltd. purchased a new stake in OraSure Technologies during the second quarter valued at about $63,000. Finally, Lazard Asset Management LLC boosted its holdings in shares of OraSure Technologies by 72.8% in the fourth quarter. Lazard Asset Management LLC now owns 7,737 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 3,260 shares during the period. Institutional investors own 97.00% of the company’s stock.
OraSure Technologies Stock Performance
Shares of OraSure Technologies stock traded up $0.20 during trading on Friday, hitting $4.56. 995,189 shares of the stock were exchanged, compared to its average volume of 1,211,830. The stock’s fifty day moving average is $3.03 and its 200 day moving average is $5.53. The stock has a market cap of $331.15 million, a PE ratio of -5.12 and a beta of 0.08. OraSure Technologies has a 12 month low of $2.62 and a 12 month high of $13.57.
OraSure Technologies (NASDAQ:OSUR – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). OraSure Technologies had a negative net margin of 24.18% and a negative return on equity of 12.92%. The company had revenue of $80.23 million during the quarter, compared to the consensus estimate of $69.91 million. The company’s revenue was up 39.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.02) earnings per share. Sell-side analysts anticipate that OraSure Technologies will post -0.63 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on OSUR shares. Citigroup reduced their price objective on OraSure Technologies from $12.00 to $10.00 in a research note on Wednesday, May 11th. StockNews.com lowered shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $12.00.
About OraSure Technologies
(Get Rating)
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
See Also
- Get a free copy of the StockNews.com research report on OraSure Technologies (OSUR)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OraSure Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and OraSure Technologies wasn’t on the list.
While OraSure Technologies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
What investors can learn from studying the past, as well as offering some ideas about asset classes with future potential.
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.
Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.
Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.
As Featured By:
MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.
Twitter Facebook StockTwits Financial Juice YouTube
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.
Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.